SmartHealth Dx announces the unveiling of SmartPath Dx at Octane's Medical Innovation Forum
IRVINE, Calif., Oct. 24, 2023 - Smart Health Diagnostics Company ("SHDx" or "the Company"), a developer of precision diagnostic tests and imaging technologies that address unmet clinical needs for advancing today's standards of care, today announced its upcoming participation in Octane's Medical Innovation Forum 2023 to discuss SmartPath Dx's impact on human health in the pathology digital space within a panel setting.
In addition, SmartPath Dx will be exhibited at two of the largest veterinary shows in Q1 2024, introducing the Company's role in the evolving field of digital pathology. SmartPath Dx technology is changing the tissue-to-digital pathology workflow.
"The field of digital pathology is expanding rapidly as conventional routines are replaced with improved productivity with less costly identification and diagnosis methods. We are focused on changing how pathology tissue sample images are prepared, processed, and viewed in just minutes," said SHDx CEO and Chairman Mitch Levine. "In addition to high-profile speaking engagements, we are showcasing our SmartPath Dx GEN2 instrument at two upcoming shows in early 2024. We look forward to introducing our SmartPath Dx instrument to a broad audience of medical professionals and operational administrators."
SmartPath Dx is a rapid glass slide-free pathology instrument designed to fundamentally transform the current standard of care and accelerate pathology diagnosis. SmartPath Dx gives pathologists crisp, high-quality direct digital images within minutes, providing actionable information for clients on-site with critical time savings and enhancement of the treatment cycle.
Upcoming and Recent Speaking Engagements
October 25, 2023:
Matthew Nuñez, SHDx President & Chief Business Officer, will join a panel of Hoag physician thought leaders and partner companies on Digital Pathology: "Back to the Present, Leap to the Future" at the Octane Medical Innovation Forum on Entrepreneurial Intelligence. The panel will provide insights into the transformation of the current pathology workflow to a new direct digital end-to-end solution facilitating improved patient outcomes, streamlining clinical workflows, and lowering healthcare costs.
October 7, 2023:
Jianyu Rao, MD, FAcadTM, professor and vice chair of the department of pathology and laboratory medicine at UCLA, recently presented on behalf of SHDx at the virtual 10th Annual Congress of the European Society for Translational Medicine (EUSTM-2023 Congress on Diagnostics, AI & ML). His "SMART Diagnostics in the Precision Care of Cancer" presentation featured SmartPath Dx, an innovative UV-based microscopic imaging instrument designed to reshape the digital pathology workflow.
Major Veterinary Upcoming Tradeshows
VMX 2024 Meeting & Expo
January 13-17, 2024
Orlando, Florida
Booth# 610
WVC Annual Conference 2024
February 18-21, 2024
Las Vegas, Nevada
Booth# 1684
About SmartHealth Dx
SmartHealth Dx ("SHDx") is a specialty diagnostics development platform company that develops, manufactures, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. SHDx's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, and imaging, to address the most challenging clinical problems. Morningstar Laboratories, a SmartHealth Dx company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services based on Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit SHDx at smarthealthdx.com, Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "termed," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law.
SOURCE SmartHealth Diagnostics, Inc.
